aluminum sulfate has been researched along with Grippe in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Farahmand, B; Forqani, M; Fotouhi, F; Hosseini, SM; Saleh, M; Shokouhi, H; Torabi, A | 1 |
| Antao, OQ; Archang, MM; Baghdasarian, S; Di Carlo, D; Kelly-Scumpia, KM; Mayer, DP; Miwa, H; Sanchez, GM; Scumpia, PO; Shang, L; Weinstein, JS | 1 |
| Anh, DD; Chien, VC; Cuong, NP; Duong, TN; Flores, J; Holt, R; Huong, VM; Montomoli, E; Phuong, NTL; Scorza, FB; Tewari, T; Thang, TC; Thiem, VD | 1 |
| Åkerman, L; Axelsson, S; Casas, R; Cheramy, M; Ludvigsson, J; Tavira, B | 1 |
| Chang, J; Kang, KW; Kim, H; Kim, JY; Kim, RH; Kwak, HW; Lee, DK; Lee, EY; Lee, SM; Nam, JH; Park, JH | 1 |
| Jeong, J; Kim, J; Kwak, C; Lee, WS; Nguyen, QT; Poo, H; Sung, MH; Yang, J | 1 |
| Hertz, T; Johnson, C; Karlsson, EA; Krammer, F; Mehle, A; Schultz-Cherry, S | 1 |
| Basser, RL; Bennet, J; Formica, NT; Hartel, G; Höschler, K; Nolan, TM; Papanaoum, K; Pearce, G; Richmond, PC; Ryan, D; Skeljo, MV; Zambon, MC | 1 |
| Huber, VC; McCullers, JA | 1 |
| Goto, S; Ikeno, D; Itamura, S; Kimachi, K; Kino, Y; Kudo, Y; Odagiri, T; Tashiro, M | 1 |
| Fang, HH; Hu, JM; Hu, YM; Li, CG; Li, W; Liang, XF; Lin, XJ; Liu, WD; Meng, FY; Pan, HX; Peng, WB; Wang, H; Wang, HQ; Xi, P; Yang, BP; Yang, JG; Zhang, X; Zhang, XF; Zheng, JS; Zhu, FC | 1 |
| BEARD, D; McLEAN, IW | 1 |
| Wadman, M | 1 |
| Nichol, KL; Treanor, JJ | 1 |
4 trial(s) available for aluminum sulfate and Grippe
| Article | Year |
|---|---|
A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).
Topics: Adjuvants, Immunologic; Adult; Alum Compounds; Antibodies, Viral; Double-Blind Method; Hemagglutination Inhibition Tests; Humans; Immunogenicity, Vaccine; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Vietnam; Virion | 2020 |
Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
Topics: Adolescent; Alum Compounds; Autoantibodies; C-Peptide; Child; Cytokines; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Finland; Glutamate Decarboxylase; Hemagglutinins; Humans; Immune System; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Insulin; Insulin Secretion; Male; Normal Distribution; Sweden; Time Factors; Vaccination; Young Adult | 2017 |
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Alum Compounds; Antibodies, Viral; Australia; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Immunization, Secondary; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Neutralization Tests; Vaccines, Inactivated; Vaccines, Subunit | 2008 |
A novel influenza A (H1N1) vaccine in various age groups.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Age Factors; Aged; Alum Compounds; Antibodies, Viral; Child; Child, Preschool; Double-Blind Method; Female; Hemagglutination Inhibition Tests; Hemagglutinins, Viral; Humans; Immunization Schedule; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Male; Middle Aged; Young Adult | 2009 |
10 other study(ies) available for aluminum sulfate and Grippe
| Article | Year |
|---|---|
Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Antibodies, Viral; Disease Models, Animal; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Mice; Mice, Inbred BALB C; Nucleocapsid Proteins; Recombinant Proteins; Vaccination; Viral Matrix Proteins | 2021 |
Improved Humoral Immunity and Protection against Influenza Virus Infection with a 3d Porous Biomaterial Vaccine.
Topics: Animals; Antibodies, Viral; Antigens; Humans; Immunity, Humoral; Influenza Vaccines; Influenza, Human; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Porosity | 2023 |
Effect of apoptosis-associated speck-like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant.
Topics: Adjuvants, Immunologic; Alum Compounds; Aluminum Hydroxide; Animals; Antibodies, Viral; Apoptosis; Caspase Activation and Recruitment Domain; Cell Proliferation; Female; Humans; Immunity, Humoral; Inflammasomes; Influenza Vaccines; Influenza, Human; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neutralization Tests; Orthomyxoviridae; Papillomavirus Vaccines; T-Lymphocytes; Vaccination; Vaccines, Inactivated | 2018 |
Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Antibodies, Viral; Antibody-Dependent Cell Cytotoxicity; Antigen Presentation; Cell Survival; Cross Reactions; Dendritic Cells; Disease Models, Animal; Humans; Immunity, Cellular; Immunity, Humoral; Immunization; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Lymph Nodes; Mice; Orthomyxoviridae Infections; Polyglutamic Acid | 2019 |
Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.
Topics: Adjuvants, Immunologic; alpha-Tocopherol; Alum Compounds; Animals; Antibodies, Neutralizing; Antibodies, Viral; Disease Models, Animal; Drug Combinations; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Influenza, Human; Mice, Inbred C57BL; Mice, Obese; Neuraminidase; Obesity; Polysorbates; Respiratory System; Squalene; Survival Analysis; Treatment Outcome; Viral Load; Viral Proteins | 2016 |
Vaccines against pandemic influenza: what can be done before the next pandemic?
Topics: Adjuvants, Immunologic; Alum Compounds; Disease Outbreaks; Hemagglutinins, Viral; Humans; Influenza A virus; Influenza Vaccines; Influenza, Human; Polysorbates; Squalene; Vaccines, Inactivated | 2008 |
A prime-boost vaccination of mice with heterologous H5N1 strains.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Antibodies, Viral; Dose-Response Relationship, Immunologic; Female; Humans; Immunization, Secondary; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Mice; Mice, Inbred BALB C; Species Specificity | 2009 |
Antibody response of swine to vaccination with formolized swine influenza virus adsorbed on alum.
Topics: Alum Compounds; Animals; Antibody Formation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Orthomyxoviridae; Swine; Vaccination | 1945 |
Race is on for flu vaccine.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Birds; Clinical Trials as Topic; Humans; Influenza A virus; Influenza in Birds; Influenza Vaccines; Influenza, Human; Polysorbates; Squalene; United States; United States Food and Drug Administration | 2005 |
Vaccines for seasonal and pandemic influenza.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Alum Compounds; Child; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Outbreaks; Health Priorities; Humans; Infant; Influenza A virus; Influenza Vaccines; Influenza, Human; Middle Aged; Polysorbates; Risk Factors; Seasons; Squalene; United States; Vaccination; Vaccines, Synthetic | 2006 |